- How is breast cancer treated?
- Surgery for breast cancer
- Radiation therapy for breast cancer
- Chemotherapy for breast cancer
- Hormone therapy for breast cancer
- Targeted therapy for breast cancer
- Bone-directed therapy for breast cancer
- Clinical trials for breast cancer
- Complementary and alternative therapies for breast cancer
- Treatment of lobular carcinoma in situ
- Treatment of ductal carcinoma in situ
- Treatment of invasive breast cancer, by stage
- Treatment of breast cancer during pregnancy
- More treatment information for breast cancer
Hormone therapy for breast cancer
Hormone therapy is another form of systemic therapy. It is most often used as an adjuvant therapy to help reduce the risk of the cancer coming back after surgery, but it can be used as neoadjuvant treatment, as well. It is also used to treat cancer that has come back after treatment or has spread.
A woman's ovaries are the main source of the hormone estrogen until menopause. After menopause, smaller amounts are still made in the body's fat tissue, where a hormone made by the adrenal gland is converted into estrogen.
Estrogen promotes the growth of cancers that are hormone receptor-positive. About 2 out of 3 of breast cancers are hormone receptor-positive — they contain receptors for the hormones estrogen (ER-positive cancers) and/or progesterone (PR-positive cancers). Most types of hormone therapy for breast cancer either lower estrogen levels or stop estrogen from acting on breast cancer cells. This kind of treatment is helpful for hormone receptor-positive breast cancers, but it does not help patients whose tumors are hormone receptor negative (both ER- and PR-negative).
If you’d like more information on a drug used in your treatment or a specific drug mentioned in this section, see our Guide to Cancer Drugs, or call us with the names of the medicines you’re taking.
Drugs that block estrogen
Tamoxifen: Tamoxifen blocks estrogen receptors in breast cancer cells. This stops estrogen from binding to them and telling the cells to grow and divide. While tamoxifen acts like an anti-estrogen in breast cells, it acts like an estrogen in other tissues, like the uterus and the bones. Because it acts like estrogen in some tissues but like an anti-estrogen in others, it is called a selective estrogen receptor modulator or SERM.
For women with hormone receptor-positive invasive breast cancer, tamoxifen can be given for 5 to 10 years after surgery to lower the chances of the cancer coming back and helping patients live longer. It also lowers the risk of a new breast cancer in the other breast. For early stage breast cancer, this drug is mainly used for women who have not yet gone through menopause. Aromatase inhibitors (discussed below) are the preferred treatment for women who have gone through menopause.
For women who have been treated for ductal carcinoma in situ (DCIS) that is hormone receptor-positive, taking tamoxifen for 5 years lowers the chance of the DCIS coming back. It also lowers the chance of getting an invasive breast cancer.
Tamoxifen can also stop the growth and even shrink tumors in women with metastatic breast cancer. It can also be used to reduce the risk of developing breast cancer in women at high risk.
This drug is taken by mouth, most often as a pill.
The most common side effects of these drugs include fatigue, hot flashes, vaginal dryness or discharge, and mood swings.
Some women with bone metastases may have a "tumor flare" with pain and swelling in the muscles and bones. This usually subsides quickly, but in some rare cases a woman may also develop a high calcium level in the blood that cannot be controlled. If this occurs, the treatment may need to be stopped for a time.
Rare, but more serious side effects are also possible. These drugs can increase the risk of developing cancers of the uterus (endometrial cancer and uterine sarcoma) in women who have gone through menopause. Tell your doctor right away about any unusual vaginal bleeding (a common symptom of both of these cancers). Most uterine bleeding is not from cancer, but this symptom always needs prompt attention.
Blood clots are another possible serious side effect. They usually form in the legs (called deep venous thrombosis or DVT), but sometimes a piece of clot may break off and end up blocking an artery in the lungs (pulmonary embolism or PE). Call your doctor or nurse right away if you develop pain, redness, or swelling in your lower leg (calf), shortness of breath, or chest pain because these can be symptoms of a DVT or PE.
Rarely, tamoxifen has been associated with strokes in post-menopausal women so tell your doctor if you have severe headaches, confusion, or trouble speaking or moving.
These drugs might also increase the risk of a heart attack.
Depending on a woman's menopausal status, tamoxifen can have different effects on the bones. In pre-menopausal women, tamoxifen can cause some bone thinning, but in post-menopausal women it is often good for bone strength.
The benefits of taking these drugs outweigh the risks for almost all women with hormone receptor-positive invasive breast cancer.
Toremifene (Fareston®): Toremifene is a drug similar to tamoxifen. It is also a SERM and has similar side effects. It is only approved to treat metastatic breast cancer. This drug is not likely to work if tamoxifen has been used and stopped working.
Fulvestrant (Faslodex®): Fulvestrant is a drug that first blocks the estrogen receptor and then also eliminates it temporarily. It is not a SERM – it acts like an anti-estrogen throughout the body.
Fulvestrant is used to treat advanced (metastatic breast cancer), most often after other hormone drugs (like tamoxifen and often an aromatase inhibitor) have stopped working.
It is given by injections into the buttocks. For the first month, the shots are given 2 weeks apart. After that, it is given once a month. Common short-term side effects can include hot flashes, night sweats, mild nausea, and fatigue .Because it blocks estrogen, in theory it could weaken bones (osteoporosis) if it is taken for a long time.
It is currently only approved by the FDA for use in post-menopausal women with advanced breast cancer that no longer responds to tamoxifen or toremifene. It is sometimes used “off-label” in pre-menopausal women, often combined with a luteinizing-hormone releasing hormone (LHRH) agonist to turn off the ovaries (see below).
Treatments to lower estrogen levels
Aromatase inhibitors (AIs): Three drugs that stop estrogen production in post-menopausal women have been approved to treat both early and advanced breast cancer: letrozole (Femara), anastrozole (Arimidex), and exemestane (Aromasin). They work by blocking an enzyme (aromatase) in fat tissue that is responsible for making small amounts of estrogen in post-menopausal women. They cannot stop the ovaries from making estrogen, so they are only effective in women whose ovaries aren’t working, either due to menopause or due to treatment with luteinizing hormone-releasing hormone analogs (these are discussed later on). AIs are taken daily as pills. So far, drugs in this group seem to work equally well in treating breast cancer.
Several studies have compared these drugs to tamoxifen as adjuvant (after surgery) hormone therapy in post-menopausal women. Using these drugs, either alone or after tamoxifen, has been shown to better reduce the risk of the cancer coming back later than using just tamoxifen for 5 years. Schedules that are known to be helpful include:
- Tamoxifen for 2 to 3 years, followed by an aromatase inhibitor (AI) to complete 5 years of treatment
- Tamoxifen for 5 years, followed by an AI for 5 years
- An AI for 5 years
Most doctors now recommend post-menopausal women whose cancers are hormone receptor–positive use an AI at some point during adjuvant therapy. Right now, standard treatment is to use these drugs for about 5 years (or alternate with tamoxifen for a total of at least 5 years). Studies now being done to see if giving an AI for more than 5 years would be more helpful.
For women with early-stage breast cancer who have not gone through menopause when they are first diagnosed, tamoxifen is often used first, and then an AI may be given later if they go through menopause during treatment. Another option is taking a drug that turns off the ovaries (a luteinizing hormone-releasing hormone analog) along with an AI.
The AIs tend to have fewer serious side effects than tamoxifen—they don't cause uterine cancers and very rarely cause blood clots. They can, however, cause muscle pain and joint stiffness and/or pain. The joint pain may be similar to a new feeling of having arthritis in many different joints at one time. This side effect may improve by switching to a different AI, but it has led some women to stop drug treatment. If this happens, most doctors recommend using tamoxifen to complete 5 years of hormone treatment.
Because aromatase inhibitors remove all estrogens from women after menopause, they also cause bone thinning, sometimes leading to osteoporosis and even fractures. Many women treated with an aromatase inhibitor are also treated with medicine to strengthen their bones, such as bisphosphonates or denosumab (these drugs are discussed in the section “Bone-directed therapy for breast cancer”).
Ovarian ablation: In pre-menopausal women, removing or shutting down the ovaries (ovarian oblation), the main source of estrogens, effectively makes the woman post-menopausal. This may allow some other hormone therapies to work better and is most often used to treat metastatic breast cancer, but has also been studied in patients with early-stage disease.
Permanent ovarian ablation can be done by surgically removing the ovaries. This operation is called an oophorectomy. More often, ovarian ablation is done with drugs called luteinizing hormone-releasing hormone (LHRH) analogs, such as goserelin (Zoladex®) or leuprolide (Lupron®). These drugs stop the signal that the body sends to ovaries to make estrogens. They can be used alone or with other hormone drugs (tamoxifen, aromatase inhibitors, fulvestrant) as hormone therapy in pre-menopausal women.
Chemotherapy drugs may also damage the ovaries of pre-menopausal women so they no longer produce estrogen. In some women, ovarian function returns months or years later, but in others, the damage to the ovaries is permanent and leads to menopause. This can sometimes be a helpful (if unintended) consequence of chemotherapy with regard to breast cancer treatment, although it leaves the woman infertile.
All of these methods can cause a woman to have symptoms of menopause, including hot flashes, night sweats, vaginal dryness, and mood swings.
Less commonly used types of hormone therapy
These options were used more often in the past, but are rarely given now. Megestrol acetate (Megace®) is a progesterone-like drug used that can be used as a hormone treatment of advanced breast cancer, usually for women whose cancers do not respond to the other hormone treatments. Its major side effect is weight gain, and it is sometimes used in higher doses to reverse weight loss for people with advanced cancer.
Androgens (male hormones) may rarely be considered after other hormone treatments for advanced breast cancer have been tried. They are sometimes effective, but they can cause masculine characteristics to develop such as an increase in body hair and a deeper voice.
Another option that may rarely be tried when the cancer is no longer responding to other hormone drugs is giving high doses of estrogen. The main risk is of serious blood clots (like DVTs and PEs). This treatment can also cause nausea.
Last Medical Review: 09/25/2014
Last Revised: 12/01/2014